MCID: GSG001
MIFTS: 53

Gas Gangrene

Categories: Infectious diseases, Muscle diseases

Aliases & Classifications for Gas Gangrene

MalaCards integrated aliases for Gas Gangrene:

Name: Gas Gangrene 12 54 43 15 37 17 71 32
Myonecrosis 12 71
Gas Bacillus Infection 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9159
ICD9CM 34 040.0
MeSH 43 D005738
SNOMED-CT 67 80466000
ICD10 32 A48.0
UMLS 71 C0017105 C0235957

Summaries for Gas Gangrene

Disease Ontology : 12 A commensal bacterial infectious disease that results in infection, located in muscle tissue, has material basis in Clostridium perfringens, which produce gas that becomes trapped in the infected tissue. Gas gangrene usually develops after injuries or surgery. The infection has symptom large blisters, has symptom pain in the infected area, has symptom myonecrosis, has symptom gas production, and has symptom sepsis.

MalaCards based summary : Gas Gangrene, also known as myonecrosis, is related to necrotizing fasciitis and myoglobinuria, and has symptoms including myoclonus, torticollis and muscle cramp. An important gene associated with Gas Gangrene is HSPG2 (Heparan Sulfate Proteoglycan 2), and among its related pathways/superpathways are Immune response Role of DAP12 receptors in NK cells and Dilated cardiomyopathy (DCM). The drugs Cilostazol and Tirofiban have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, colon and liver, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Gas gangrene (also known as clostridial myonecrosis and myonecrosis) is a bacterial infection that... more...

Related Diseases for Gas Gangrene

Diseases related to Gas Gangrene via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 351)
# Related Disease Score Top Affiliating Genes
1 necrotizing fasciitis 30.8 PRF1 PIK3C2A CRP
2 myoglobinuria 30.8 PIK3C2A MB DMD
3 compartment syndrome 30.7 PIK3C2A MB CRP
4 disseminated intravascular coagulation 30.6 PIK3C2A MB CRP CPB2
5 pyomyositis 30.6 PIK3C2A MB CRP
6 myositis 30.5 SERPINA3 PIK3C2A MB DMD
7 toxic myocarditis 30.5 TNNI3 PIK3C2A
8 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 30.3 PIK3C2A MB
9 aspiration pneumonia 30.3 SERPINA3 PIK3C2A CRP
10 anuria 30.3 PIK3C2A MB CRP
11 acute pancreatitis 30.3 SERPINA3 PLA2G2A PLA2G1B CRP CPB1
12 endocarditis 30.2 TNNI3 PIK3C2A CRP
13 angina pectoris 30.1 TNNI3 PIK3C2A MB CRP
14 pericarditis 30.0 TNNT2 TNNI3 PIK3C2A CRP
15 atrial standstill 1 30.0 TNNT2 TNNI3 DMD
16 muscular dystrophy, duchenne type 29.9 TNNT2 TNNI3 PIK3C2A MB DMD DAG1
17 respiratory failure 29.9 SERPINA3 PIK3C2A DMD CRP
18 lipoprotein quantitative trait locus 29.8 TNNT2 TNNI3 PIK3C2A MB EEF1A2 CRP
19 muscular dystrophy 29.8 TNNT2 TNNI3 PIK3C2A MB HSPG2 DMD
20 pulmonary embolism 29.7 TNNT2 TNNI3 MB CRP CPB2
21 acute myocardial infarction 29.6 TNNT2 TNNI3 SERPINA3 PIK3C2A MB CRP
22 myocarditis 29.6 TNNI3 PRF1 PIK3C2A MB DMD DAG1
23 myopathy 29.5 TNNT2 TNNI3 SERPINA3 PIK3C2A MB HSPG2
24 intermediate coronary syndrome 29.5 TNNT2 TNNI3 PIK3C2A MB EEF1A2 CRP
25 pneumonia 29.3 PRF1 PLA2G1B PIK3C2A NEU1 MB CRP
26 hypertrophic cardiomyopathy 29.3 TNNT2 TNNI3 PIK3C2A MB DMD DAG1
27 anthrax disease 11.5
28 tetanus 10.5
29 virus associated hemophagocytic syndrome 10.5 PIK3C2A MB
30 epidemic pleurodynia 10.5 PIK3C2A MB
31 anteroseptal myocardial infarction 10.5 PIK3C2A MB
32 cardiogenic shock 10.5 PIK3C2A CRP
33 malignant granular cell myoblastoma 10.5 SERPINA3 MB
34 orbital plasma cell granuloma 10.5 PIK3C2A CRP
35 familial isolated restrictive cardiomyopathy 10.5 TNNT2 TNNI3
36 cellulitis 10.5
37 malignant mesenchymoma 10.5 SERPINA3 MB
38 inferior myocardial infarction 10.4 TNNI3 PIK3C2A
39 progressive muscular dystrophy 10.4 MB DMD
40 gastric dilatation 10.4 TNNI3 CRP
41 chronic thromboembolic pulmonary hypertension 10.4 CRP CPB2
42 toxic shock syndrome 10.4
43 ornithosis 10.4 PIK3C2A CRP ALLC
44 collagen disease 10.4 SERPINA3 HSPG2 CRP
45 aspiration pneumonitis 10.4 SERPINA3 CRP
46 cardiac tamponade 10.4 TNNI3 PIK3C2A CRP
47 creatine phosphokinase, elevated serum 10.4 PIK3C2A MB DMD
48 pericardial effusion 10.4 TNNI3 PIK3C2A CRP
49 atypical depressive disorder 10.4 SERPINA3 CRP
50 panophthalmitis 10.3

Comorbidity relations with Gas Gangrene via Phenotypic Disease Network (PDN):


Acute Cystitis Decubitus Ulcer
Deficiency Anemia Heart Disease
Peripheral Vascular Disease

Graphical network of the top 20 diseases related to Gas Gangrene:



Diseases related to Gas Gangrene

Symptoms & Phenotypes for Gas Gangrene

UMLS symptoms related to Gas Gangrene:


myoclonus, torticollis, muscle cramp

GenomeRNAi Phenotypes related to Gas Gangrene according to GeneCards Suite gene sharing:

26 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.8 PIK3C2A
2 Decreased viability GR00055-A-2 9.8 PIK3C2A
3 Decreased viability GR00055-A-3 9.8 PIK3C2A
4 Decreased viability GR00221-A-1 9.8 PIK3C2A
5 Decreased viability GR00221-A-2 9.8 PIK3C2A
6 Decreased viability GR00221-A-4 9.8 PIK3C2A
7 Decreased viability GR00240-S-1 9.8 PIK3C2A PSMA6
8 Decreased viability GR00249-S 9.8 CPB1 DAG1 PIK3C2A PLA2G10 PSMA6 SERPINA3
9 Decreased viability GR00342-S-1 9.8 PIK3C2A
10 Decreased viability GR00342-S-2 9.8 PIK3C2A
11 Decreased viability GR00342-S-3 9.8 PIK3C2A
12 Decreased viability GR00381-A-1 9.8 ALLC NEU1 PSMA6
13 Decreased viability GR00386-A-1 9.8 DAG1 MB NEU1 PLA2G10 PSMA6
14 Decreased viability GR00402-S-2 9.8 DMD HSPG2 PLA2G1B PSMA6

MGI Mouse Phenotypes related to Gas Gangrene:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.03 CPE CRP DAG1 DMD HSPG2 MB
2 growth/size/body region MP:0005378 9.97 CPB2 CPE DAG1 DMD EEF1A2 HSPG2
3 homeostasis/metabolism MP:0005376 9.8 CPB2 CPE CRP DAG1 DMD HSPG2
4 muscle MP:0005369 9.32 CPE DAG1 DMD EEF1A2 HSPG2 MB

Drugs & Therapeutics for Gas Gangrene

Drugs for Gas Gangrene (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
2
Tirofiban Approved Phase 4 144494-65-5 60947
3
Dipyridamole Approved Phase 4 58-32-2 3108
4
Colchicine Approved Phase 4 64-86-8 2833 6167
5
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
6
Atorvastatin Approved Phase 4 134523-00-5 60823
7
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
8
Eptifibatide Approved, Investigational Phase 4 188627-80-7 123610
9 Neurotransmitter Agents Phase 4
10 Purinergic P2Y Receptor Antagonists Phase 4
11 Vasodilator Agents Phase 4
12 Analgesics Phase 4
13 Fibrinolytic Agents Phase 4
14 Pharmaceutical Solutions Phase 4
15 Phosphodiesterase Inhibitors Phase 4
16 Respiratory System Agents Phase 4
17 Phosphodiesterase 3 Inhibitors Phase 4
18 Anti-Asthmatic Agents Phase 4
19 Analgesics, Non-Narcotic Phase 4
20 Neuroprotective Agents Phase 4
21 Antipyretics Phase 4
22 Cyclooxygenase Inhibitors Phase 4
23 Bronchodilator Agents Phase 4
24 Protective Agents Phase 4
25 Anti-Inflammatory Agents, Non-Steroidal Phase 4
26 Tubulin Modulators Phase 4
27 Anti-Inflammatory Agents Phase 4
28 Antirheumatic Agents Phase 4
29 Antimitotic Agents Phase 4
30 Lipid Regulating Agents Phase 4
31 Hypolipidemic Agents Phase 4
32 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
33 Anticholesteremic Agents Phase 4
34 Antimetabolites Phase 4
35 Platelet Aggregation Inhibitors Phase 4
36
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
37
Bivalirudin Approved, Investigational Phase 3 128270-60-0 16129704
38
Ticagrelor Approved Phase 3 274693-27-5 9871419
39
Adenosine Approved, Investigational Phase 3 58-61-7 60961
40 Antithrombins Phase 3
41 Antithrombin III Phase 3
42 Serine Proteinase Inhibitors Phase 3
43
protease inhibitors Phase 3
44 HIV Protease Inhibitors Phase 3
45 calcium heparin Phase 3
46 Anticoagulants Phase 3
47 Rosuvastatin Calcium Phase 3 147098-20-2
48 Calcium, Dietary Phase 3
49 Anti-Arrhythmia Agents Phase 3
50
Serine Investigational, Nutraceutical Phase 3 56-45-1 5951

Interventional clinical trials:

(show all 34)
# Name Status NCT ID Phase Drugs
1 Side Branch Predilatation Strategy in Coronary Bifurcation Lesion Stenting (SBPS) Unknown status NCT01430377 Phase 4
2 BIfurcation Optimal Treatment Strategy With LIMus Eluting Dedicated Bifurcation Versus Convention Stent Randomized Study Unknown status NCT01430364 Phase 4
3 ACCELerated Inhibition of Platelet Aggregation, Inflammation and Ischemia-reperfusion Injury by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome Completed NCT01354808 Phase 4 Dual Anti-Platelet Therapy (DAPT);Triple Anti-Platelet Therapy (TAPT)
4 Safety and Efficacy of Peri-procedural Use of Tirofiban in Elective Percutaneous Coronary Intervention for Long Coronary Lesions With Overlapping Drug-Eluting Stent Completed NCT01498003 Phase 4 tirofiban;normal saline solution
5 Does Pretreatment With Persantin Reduce Periprocedural Troponin-I Release in Patients Undergoing Elective Single Vessel PCI Completed NCT00767663 Phase 4 dipyridamole;placebo
6 Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism Completed NCT00915733 Phase 4 cilostazol;clopidogrel (Plavix);aspirin (Acetylsalicylic acid)
7 Anti-inflammatory Effects of Colchicine in Patients Undergoing Percutaneous Coronary Intervention: Inflammatory Marker Substudy of the Colchicine-PCI Trial Active, not recruiting NCT01709981 Phase 4 Colchicine;Placebo
8 Research Evaluation to Study Individuals Who Show Thromboxane Or P2Y12 Receptor Resistance Terminated NCT00289601 Phase 4 eptifibatide
9 Effects of Single-Dose Atorvastatin on Peri-Procedural Myonecrosis During Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes - The NO-MI Study Terminated NCT00344019 Phase 4 Placebo Oral Tablet;Atorvastatin 80mg
10 Randomized Comparison of Adenosin Intracoronary Infusion and Clopidogrel Pretreatment on Myonecrosis Occurence in Elective PCI Unknown status NCT00751491 Phase 3 Adenosin;Clopidogrel
11 Bivalirudin Plus Stenting in Long Lesion to Avoid Periprocedural Myocardial Necrosis Trial Unknown status NCT01555658 Phase 3 Bivalirudin;Unfractioned Heparin
12 High Loading ROsuvastatin Pretreatment in Patients Undergoing Elective PCI to Reduce the Incidence of MyocArdial Periprocedural Necrosis : Comparison With Atorvastatin High Dose Reloading. Completed NCT01228227 Phase 3 ATORVASTATIN 80 mg;ROSUVASTATIN 40 mg
13 Prevention of Cardiac and Vascular Periprocedural Complications in Patients Undergoing Coronary Angiography or Angioplasty: Intracoronary Adenosine Administration to Prevent Periprocedural Myonecrosis in Elective Coronary Angioplasty. A Prospective Double-blind Randomized Trial. Completed NCT01148147 Phase 3 Adenosine;Placebo
14 ROsuvastatin Pretreatment in Patients Undergoing Elective PCI to Reduce the Incidence of MyocArdial Periprocedural Necrosis Completed NCT01007279 Phase 3 ROSUVASTATIN
15 Optimal P2Y12-receptor treatmeNt Guided by bedSIDe Genetic or Pharmacodynamic TESTing to Prevent Periprocedural Myonecrosis During Elective Percutaneous Coronary Intervention. Recruiting NCT01930773 Phase 3
16 Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting: The ALPHEUS Study Recruiting NCT02617290 Phase 3 Ticagrelor;Clopidogrel
17 Prophylactic Intra-coronary Adenosine to Prevent Post Coronary Artery Stenting Myonecrosis Terminated NCT00612521 Phase 3 Adenosine
18 A Randomized, Multi-center, Prospective, Double Blind, Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema Unknown status NCT01794182 Phase 2 RP-1127 (Glyburide for Injection)
19 Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial Completed NCT02111161 Phase 2 IVIG (Privigen);Saline 0.9%
20 A Prospective, Non-Randomized, Open-Label Study on the Clinical Effects of Hyperbaric Oxygen Therapy in Thai Autistic Children Completed NCT00670891 Phase 1
21 The Registry of Hyperbaric Oxygen Therapy Treated Patients Unknown status NCT02483650
22 Pharmacologic Treatment of Myocardial Ischemia Detected by Intracoronary ECG Unknown status NCT03383393 Intracoronary bolus of adenosine (adenocor), Integrilin (eptifibatide) or nitroglyzerin (nitronal)
23 Effects of Repetitive Hyperbaric Oxygen Therapy in Patients With Acute Ischaemic Stroke Unknown status NCT03431402 Hyperbaric oxygen
24 Assessment of Vessel Healing After DES Implantation With STEMI, NSTEMI and Stable/Unstable Angina Patients: a Randomized Study Between Everolimus and Biolimus A9-eluting Stents: an Optical Coherence Tomography (OCT) and Intravascular Ultrasound Tissue Characterisation (IVUS-TC) Study Unknown status NCT01065519
25 COronary SIde Branch Residual IschemiA and COllateralization Assessment Study (COSIBRIA & Co Study) Completed NCT01268228
26 Biomarkers in Necrotizing Soft Tissue Infections - Effects of Hyperbaric Oxygen Treatment on the Immune Response Completed NCT02501382
27 Remote Myocardial Ischemic Preconditioning in Humans Completed NCT00588042
28 Angiotensin Converting Enzyme Inhibitor Therapy and Periprocedural Myocardial Infarction in Patients With Metabolic Syndrome Completed NCT02054390
29 Biomarkers in Necrotizing Soft Tissue Infections - Aspects of the Innate Immune Response Completed NCT02180906
30 Prospective Partially Randomized Comparison of Clopidogrel Loading Versus Maintenance Dosing to Prevent Periprocedural Myocardial Infarction After Stenting for a Stable Angina Pectoris Completed NCT03759067 clopidogrel 75mg;Clopidogrel 300 mg;clopidogrel 600mg
31 ProTreat - Prognosis and Treatment of Necrotizing Soft Tissue Infections: A Prospective Cohort Study Completed NCT03147352
32 Fractional Flow Reserve Versus Intracoronary ECG for Detection of Post Stenting Ischemia in Side Branch Territory in coronAry Bifurcation Lesions Recruiting NCT01724957
33 The Bioelectrical Impedance Analysis and Muscular Ultrasound in the Detection of Nutritional Status in Critically Ill Patients: The BUS Study Recruiting NCT03924232
34 Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After PCI Terminated NCT00979940 Atorvastatin

Search NIH Clinical Center for Gas Gangrene

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Gas Gangrene cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Gas Gangrene:
Peripheral blood-derived hematopoietic stem cells for leg gangrene
Embryonic/Adult Cultured Cells Related to Gas Gangrene:
Peripheral blood-derived hematopoietic stem cells

Cochrane evidence based reviews: gas gangrene

Genetic Tests for Gas Gangrene

Anatomical Context for Gas Gangrene

MalaCards organs/tissues related to Gas Gangrene:

40
Skeletal Muscle, Colon, Liver, Skin, Heart, Brain, Testes

Publications for Gas Gangrene

Articles related to Gas Gangrene:

(show top 50) (show all 3114)
# Title Authors PMID Year
1
Enhanced production of phospholipase C and perfringolysin O (alpha and theta toxins) in a gatifloxacin-resistant strain of Clostridium perfringens. 54 61
18160514 2008
2
Clostridium perfringens phospholipase C-induced platelet/leukocyte interactions impede neutrophil diapedesis. 61 54
16585634 2006
3
Clostridial gas gangrene. I. Cellular and molecular mechanisms of microvascular dysfunction induced by exotoxins of Clostridium perfringens. 54 61
10950774 2000
4
Photobiomodulation reduces cell death and cytokine production in C2C12 cells exposed to Bothrops venoms. 61
31754908 2020
5
Toxinological characterization of venom from Leptodeira annulata (Banded cat-eyed snake; Dipsadidae, Imantodini). 61
32302625 2020
6
What Every Neuropathologist Needs to Know: The Muscle Biopsy. 61
32529201 2020
7
MYONECROSIS AND DEATH DUE TO PRESUMED MICROCYSTIN TOXICOSIS IN AMERICAN WHITE PELICANS (PELECANUS ERYTHRORHYNCOS). 61
32549572 2020
8
Procedural microvascular activation in long lesions treated with bioresorbable vascular scaffolds or everolimus-eluting stents: the PROACTIVE trial. 61
31085503 2020
9
A rare cause of pneumoperitoneum due to clostridium perfringens in a cirrhotic patient. 61
32564712 2020
10
Diabetic myonecrosis: an unusual mimicker of idiopathic inflammatory myositis. 61
32568286 2020
11
Implications of increased S100β and Tau5 proteins in dystrophic nerves of two mdx mouse models for Duchenne muscular dystrophy. 61
32240725 2020
12
Upper extremity exertional rhabdomyolysis: MR imaging findings in four cases. 61
32346455 2020
13
The Agr-Like Quorum-Sensing System Is Important for Clostridium perfringens Type A Strain ATCC 3624 To Cause Gas Gangrene in a Mouse Model. 61
32554714 2020
14
Non-traumatic gas gangrene due to Clostridium sporogenes. 61
32473146 2020
15
Emerging erythromycin and clindamycin resistance in group A streptococcus: Efficacy of linezolid and tedizolid in experimental necrotizing infection. 61
32408046 2020
16
Spontaneous Non-Traumatic Clostridium perfringens Sepsis. 61
31875607 2020
17
Relationship between high sensitivity C-reactive protein and angiographic severity of coronary artery disease. 61
32547608 2020
18
Clostridium septicum-infected aortic aneurysm or graft is a deadly diagnosis. 61
31843297 2020
19
Intensive Care Unit-Acquired Weakness: Neuropathology. 61
32358244 2020
20
A case report of iatrogenic gas gangrene post colonoscopy successfully treated with conservative management- is surgery always necessary? 61
32460761 2020
21
An Unusual Case of Hydrogen Peroxide-Induced Injury Presenting With Gas Gangrene. 61
32366741 2020
22
Diabetic Myonecrosis: A Poorly Recognized Complication in an Adult With Type 2 Diabetes. 61
31474461 2020
23
Impact of Immunosuppression on Acute Left Ventricular Function Recovery and ECMO Use in Patients with Fulminant Viral Myocarditis: An "All-In" Strategy. 61
32465972 2020
24
Pharmacodynamic study of prasugrel or clopidogrel in non-ST-elevation acute coronary syndrome with CYP2C19 genetic variants undergoing percutaneous coronary intervention (PRAISE-GENE trial). 61
32029306 2020
25
Factors associated with myonecrosis at time of fasciotomy in acute leg compartment syndrome. 61
32350597 2020
26
Postmortem computed tomography of gas gangrene with aortic gas in a dialysis patient. 61
32323214 2020
27
[Interesting Case: Sucking wound of the upper limb simulating gas-gangrene]. 61
31931545 2020
28
Clostridium sordellii-associated gas gangrene in 8 horses, 1998-2019. 61
31585515 2020
29
Immunization of rabbits with recombinant Clostridium perfringens alpha toxins CPA-C and CTB-CPA-C in a bicistronic design expression system confers strong protection against challenge. 61
31811913 2020
30
Clinical and histological features of immune-mediated necrotising myopathy: A multi-centre South Australian cohort study. 61
32229165 2020
31
Neuralgic Amyotrophy Presenting with Multifocal Myonecrosis and Rhabdomyolysis. 61
32337110 2020
32
Biomarkers for Duchenne muscular dystrophy: myonecrosis, inflammation and oxidative stress. 61
32224496 2020
33
Paeniclostridium (Clostridium) sordellii-associated enterocolitis in 7 horses. 61
32052697 2020
34
The antibiotic susceptibility pattern of gas gangrene-forming Clostridium spp. clinical isolates from South-Eastern Hungary. 61
31778089 2020
35
Clostridium Perfringens in Gas Gangrene: Still a Smoked Gun! 61
32435613 2020
36
Gas gangrene, diabetes and amputations of upper extremities. 61
32191653 2020
37
Gas gangrene in mammals: a review. 61
32081096 2020
38
Tudor military surgery and the management of Sir Martin Frobisher's gunshot wound: Comparison with current treatment. 61
32044118 2020
39
First report of an idiopathic partial tail myonecrosis in European brown shrimp Crangon crangon caught in the North Sea. 61
32103821 2020
40
Myotoxicity induced by Cerastes cerastes venom: Beneficial effect of heparin in skeletal muscle tissue regeneration. 61
31738878 2020
41
Comparative study of calcium and calcium-related enzymes with differentiation markers in different ages and muscle types in mdx mice. 61
31274171 2020
42
Concurrent Guillain-Barré syndrome and myositis complicating dengue fever. 61
32047085 2020
43
Impending hand compartment syndrome in an infant: is clinical evaluation enough to perform a fasciotomy? 61
32128201 2020
44
The EngCP endo α-N-acetylgalactosaminidase is a virulence factor involved in Clostridium perfringens gas gangrene infections. 61
31987726 2020
45
Could the "watchful waiting" approach in a patient with gas gangrene save the lower limb? 61
32103658 2020
46
Dead Meat: Glecaprevir/Pibrentasvir-Induced Statin Myonecrosis. 61
31894484 2020
47
Diabetic Myonecrosis of the Thigh Mimicking an Infected Hematoma. 61
32251049 2020
48
Retrospective Study of Traumatic Intra-Interspecific Interactions in Stranded Cetaceans, Canary Islands. 61
32181264 2020
49
Development of Nanobodies Against Hemorrhagic and Myotoxic Components of Bothrops atrox Snake Venom. 61
32457735 2020
50
Diabetic Myonecrosis: An Uncommon Complication of a Common Condition. 61
32206637 2020

Variations for Gas Gangrene

Expression for Gas Gangrene

Search GEO for disease gene expression data for Gas Gangrene.

Pathways for Gas Gangrene

Pathways related to Gas Gangrene according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.21 PRF1 PLA2G2A PLA2G1B PLA2G10
2
Show member pathways
11.89 TNNT2 TNNI3 DMD DAG1
3 11.56 TNNT2 TNNI3 HSPG2
4 11.4 TNNT2 TNNI3 DMD
5
Show member pathways
11.13 PLA2G2A PLA2G1B PLA2G10
6 11.03 PLA2G2A PLA2G1B PLA2G10 CPB2 CPB1
7
Show member pathways
10.99 PLA2G2A PLA2G1B PLA2G10
8 10.41 HSPG2 DMD DAG1

GO Terms for Gas Gangrene

Cellular components related to Gas Gangrene according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.85 SERPINA3 PSMA6 PLA2G2A PIK3C2A NEU1 MB
2 extracellular space GO:0005615 9.65 SERPINA3 PLA2G2A PLA2G1B PLA2G10 HSPG2 DAG1
3 secretory granule GO:0030141 9.63 PLA2G2A PLA2G1B DMD
4 sarcomere GO:0030017 9.58 TNNT2 TNNI3 PSMA6
5 myofibril GO:0030016 9.5 TNNI3 PSMA6 DMD
6 dystrophin-associated glycoprotein complex GO:0016010 9.48 DMD DAG1
7 troponin complex GO:0005861 9.43 TNNT2 TNNI3
8 extracellular region GO:0005576 9.4 SERPINA3 PRF1 PLA2G2A PLA2G1B PLA2G10 NEU1
9 cardiac myofibril GO:0097512 9.37 TNNT2 TNNI3
10 cardiac Troponin complex GO:1990584 9.26 TNNT2 TNNI3

Biological processes related to Gas Gangrene according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 9.93 PLA2G2A PLA2G1B PLA2G10 NEU1 HSPG2
2 defense response to Gram-positive bacterium GO:0050830 9.73 PLA2G2A PLA2G1B CRP
3 lipid catabolic process GO:0016042 9.71 PLA2G2A PLA2G1B PLA2G10 NEU1
4 phospholipid metabolic process GO:0006644 9.67 PLA2G2A PLA2G1B PLA2G10
5 cardiac muscle contraction GO:0060048 9.65 TNNT2 TNNI3 DMD
6 phosphatidic acid biosynthetic process GO:0006654 9.63 PLA2G2A PLA2G1B PLA2G10
7 muscle filament sliding GO:0030049 9.61 TNNT2 TNNI3 DMD
8 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.57 PLA2G2A PLA2G10
9 phosphatidylcholine metabolic process GO:0046470 9.55 PLA2G2A PLA2G1B
10 phosphatidylcholine acyl-chain remodeling GO:0036151 9.54 PLA2G2A PLA2G1B PLA2G10
11 negative regulation of ATPase activity GO:0032780 9.52 TNNT2 TNNI3
12 response to denervation involved in regulation of muscle adaptation GO:0014894 9.51 DMD DAG1
13 phosphatidylethanolamine acyl-chain remodeling GO:0036152 9.5 PLA2G2A PLA2G1B PLA2G10
14 arachidonic acid secretion GO:0050482 9.43 PLA2G2A PLA2G1B PLA2G10
15 phosphatidylserine acyl-chain remodeling GO:0036150 9.33 PLA2G2A PLA2G1B PLA2G10
16 phosphatidylinositol acyl-chain remodeling GO:0036149 9.13 PLA2G2A PLA2G1B PLA2G10
17 phosphatidylglycerol acyl-chain remodeling GO:0036148 8.8 PLA2G2A PLA2G1B PLA2G10

Molecular functions related to Gas Gangrene according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 metal ion binding GO:0046872 10.23 TNNI3 PRF1 PLA2G2A PLA2G1B PLA2G10 MB
2 hydrolase activity GO:0016787 9.97 PSMA6 PLA2G2A PLA2G1B PLA2G10 NEU1 CPE
3 carboxypeptidase activity GO:0004180 9.65 CPE CPB2 CPB1
4 phospholipase A2 activity GO:0004623 9.58 PLA2G2A PLA2G1B PLA2G10
5 metallocarboxypeptidase activity GO:0004181 9.54 CPE CPB2 CPB1
6 vinculin binding GO:0017166 9.51 DMD DAG1
7 dystroglycan binding GO:0002162 9.49 DMD DAG1
8 troponin C binding GO:0030172 9.43 TNNT2 TNNI3
9 phospholipase A2 activity consuming 1,2-dioleoylphosphatidylethanolamine) GO:0102568 9.43 PLA2G2A PLA2G1B PLA2G10
10 phospholipase A2 activity (consuming 1,2-dipalmitoylphosphatidylcholine) GO:0102567 9.33 PLA2G2A PLA2G1B PLA2G10
11 calcium ion binding GO:0005509 9.23 TNNT2 PRF1 PLA2G2A PLA2G1B PLA2G10 HSPG2
12 calcium-dependent phospholipase A2 activity GO:0047498 9.13 PLA2G2A PLA2G1B PLA2G10

Sources for Gas Gangrene

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....